Delayed progression of lung metastases following delivery of a prodrug-activating enzyme

Research output: Contribution to journalArticle

Abstract

Background: Chemotherapy is an effective option to treat recurrent or metastatic cancer but its debilitating sideeffects limit the dose and time of exposure. Prodrugs that can be activated locally by an activating enzyme can minimize collateral damage from chemotherapy. We previously demonstrated the efficacy of a poly-L-lysine-based theranostic nanoplex containing bacterial cytosine deaminase (bCD) that locally converted 5-fluorocytosine (5-FC) to the chemotherapeutic agent 5-fluorouracil in MDA-MB-231 primary tumor xenografts. Materials and Methods: Here we used a more effective variant of bCD to target metastatic red fluorescence protein expressing MDA-MB-435 cells in the lungs. We used an intravenous injection of tumor cells and monitored tumor growth in the lungs for 5 weeks by which time metastatic nodules were detected with optical imaging. The animals were then treated with the bCD-nanoplex and 5-FC. Results: We observed a significant decrease in metastatic burden with a single dose of the enzyme-nanoplex and two consecutive prodrug injections. Conclusion: These results are a first step towards the longitudinal evaluation of such a strategy with multiple doses. Additionally, the enzyme can be directly coupled to imaging reporters to time prodrug administration for the detection and treatment of aggressive metastatic cancer.

LanguageEnglish (US)
Pages2195-2200
Number of pages6
JournalAnticancer Research
Volume37
Issue number5
DOIs
StatePublished - May 1 2017

Fingerprint

Prodrugs
Cytosine Deaminase
Neoplasm Metastasis
Lung
Enzymes
Flucytosine
Neoplasms
Drug Therapy
Optical Imaging
Heterografts
Intravenous Injections
Fluorouracil
Lysine
Fluorescence
Injections
Growth
Proteins

Keywords

  • Cytosine deaminase
  • Imaging
  • Lung cancer
  • Metastasis
  • Prodrug enzyme therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Delayed progression of lung metastases following delivery of a prodrug-activating enzyme. / Dore-Savard, Louis; Chen, Zhihang; Winnard, Paul T.; Krishnamachary, Balaji; Raman, Venu; Black, Margaret E.; Bhujwalla, Zaver M.

In: Anticancer Research, Vol. 37, No. 5, 01.05.2017, p. 2195-2200.

Research output: Contribution to journalArticle

@article{30a77c839c7542b8b6bbcc18cae78e54,
title = "Delayed progression of lung metastases following delivery of a prodrug-activating enzyme",
abstract = "Background: Chemotherapy is an effective option to treat recurrent or metastatic cancer but its debilitating sideeffects limit the dose and time of exposure. Prodrugs that can be activated locally by an activating enzyme can minimize collateral damage from chemotherapy. We previously demonstrated the efficacy of a poly-L-lysine-based theranostic nanoplex containing bacterial cytosine deaminase (bCD) that locally converted 5-fluorocytosine (5-FC) to the chemotherapeutic agent 5-fluorouracil in MDA-MB-231 primary tumor xenografts. Materials and Methods: Here we used a more effective variant of bCD to target metastatic red fluorescence protein expressing MDA-MB-435 cells in the lungs. We used an intravenous injection of tumor cells and monitored tumor growth in the lungs for 5 weeks by which time metastatic nodules were detected with optical imaging. The animals were then treated with the bCD-nanoplex and 5-FC. Results: We observed a significant decrease in metastatic burden with a single dose of the enzyme-nanoplex and two consecutive prodrug injections. Conclusion: These results are a first step towards the longitudinal evaluation of such a strategy with multiple doses. Additionally, the enzyme can be directly coupled to imaging reporters to time prodrug administration for the detection and treatment of aggressive metastatic cancer.",
keywords = "Cytosine deaminase, Imaging, Lung cancer, Metastasis, Prodrug enzyme therapy",
author = "Louis Dore-Savard and Zhihang Chen and Winnard, {Paul T.} and Balaji Krishnamachary and Venu Raman and Black, {Margaret E.} and Bhujwalla, {Zaver M.}",
year = "2017",
month = "5",
day = "1",
doi = "10.21873/anticanres.11554",
language = "English (US)",
volume = "37",
pages = "2195--2200",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - Delayed progression of lung metastases following delivery of a prodrug-activating enzyme

AU - Dore-Savard,Louis

AU - Chen,Zhihang

AU - Winnard,Paul T.

AU - Krishnamachary,Balaji

AU - Raman,Venu

AU - Black,Margaret E.

AU - Bhujwalla,Zaver M.

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Background: Chemotherapy is an effective option to treat recurrent or metastatic cancer but its debilitating sideeffects limit the dose and time of exposure. Prodrugs that can be activated locally by an activating enzyme can minimize collateral damage from chemotherapy. We previously demonstrated the efficacy of a poly-L-lysine-based theranostic nanoplex containing bacterial cytosine deaminase (bCD) that locally converted 5-fluorocytosine (5-FC) to the chemotherapeutic agent 5-fluorouracil in MDA-MB-231 primary tumor xenografts. Materials and Methods: Here we used a more effective variant of bCD to target metastatic red fluorescence protein expressing MDA-MB-435 cells in the lungs. We used an intravenous injection of tumor cells and monitored tumor growth in the lungs for 5 weeks by which time metastatic nodules were detected with optical imaging. The animals were then treated with the bCD-nanoplex and 5-FC. Results: We observed a significant decrease in metastatic burden with a single dose of the enzyme-nanoplex and two consecutive prodrug injections. Conclusion: These results are a first step towards the longitudinal evaluation of such a strategy with multiple doses. Additionally, the enzyme can be directly coupled to imaging reporters to time prodrug administration for the detection and treatment of aggressive metastatic cancer.

AB - Background: Chemotherapy is an effective option to treat recurrent or metastatic cancer but its debilitating sideeffects limit the dose and time of exposure. Prodrugs that can be activated locally by an activating enzyme can minimize collateral damage from chemotherapy. We previously demonstrated the efficacy of a poly-L-lysine-based theranostic nanoplex containing bacterial cytosine deaminase (bCD) that locally converted 5-fluorocytosine (5-FC) to the chemotherapeutic agent 5-fluorouracil in MDA-MB-231 primary tumor xenografts. Materials and Methods: Here we used a more effective variant of bCD to target metastatic red fluorescence protein expressing MDA-MB-435 cells in the lungs. We used an intravenous injection of tumor cells and monitored tumor growth in the lungs for 5 weeks by which time metastatic nodules were detected with optical imaging. The animals were then treated with the bCD-nanoplex and 5-FC. Results: We observed a significant decrease in metastatic burden with a single dose of the enzyme-nanoplex and two consecutive prodrug injections. Conclusion: These results are a first step towards the longitudinal evaluation of such a strategy with multiple doses. Additionally, the enzyme can be directly coupled to imaging reporters to time prodrug administration for the detection and treatment of aggressive metastatic cancer.

KW - Cytosine deaminase

KW - Imaging

KW - Lung cancer

KW - Metastasis

KW - Prodrug enzyme therapy

UR - http://www.scopus.com/inward/record.url?scp=85019143194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019143194&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11554

DO - 10.21873/anticanres.11554

M3 - Article

VL - 37

SP - 2195

EP - 2200

JO - Anticancer Research

T2 - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5

ER -